Table 1.
Characteristics of included trials.
| Reference | Settings | Study Period | Study Design | Study Population |
Median Age | Female % |
|---|---|---|---|---|---|---|
| Apostolescu 2001 [20] | Romania | 2000 | RCT double blind: 15 LVD and 16 not | 31 | No reported | No reported |
| Kumar 2007 [21] | India | January 2002 to March 2005 | RCT double blind: 31 LVD and 40 placebo | 71 | LVD: 37.2 plac: 36.4 |
LVD: 35.5 plac: 20 |
| Yu 2010 [22] | China | September 2006 to May 2008 | Consecutive hospitalized patients randomly assigned in a 1:1 ratio according to the admission order: 40 LVD and 40 SOC | 80 | LVD: 45.8 SOC: 44.5 |
LVD: 25 SOC: 28 |
| Wiegand 2014 [23] | Germany | December 2006 to December 2008 | RCT multicentre (24 centres) double blind: 18 LVD and 17 placebo | 35 | LVD: 39 plac: 42 |
LVD: 6 plac: 23 |
| Streinu-Cercel 2016 [24] | Romania | May 2005 to May 2009 | Open-label RCT: 69 LVD, 21 ECV and 110 SOC | 200 | LVD: 37.9 ECV: 34.8 SOC: 35.2 |
LVD: 42 ECV: 49 SOC: 62 |
RCT: Randomized Clinical Trial. LVD: Lamivudine. ECV: Entecavir. SOC: Standard-of-care.